Market research
CYCN Cyclerion Therapeutics Inc
PINK USD Healthcare
Latest close
As of 14 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 56
- Dividend yield
- Not available
- Beta
- 1.75
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 56
- Dividend yield
- Not available
- Beta
- 1.75
About
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Research context
Cyclerion Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CYCN discussion.
5 years, 6 months ago
Cyclerion Therapeutics, Inc is currently in a long term uptrend where the price is trading 7.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.2.
Cyclerion Therapeutics, Inc's total revenue sank by 91.0% to $133K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-19K since the same quarter in the previous year.
Finally, its free cash flow grew by 37.0% to $-14M since the same quarter in the previous year.
Based on the above factors, Cyclerion Therapeutics, Inc gets an overall score of 4/5.